Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab Combined With BCG After TURBT in High-risk NMIBC
NCT07307456Phase 2Recruiting
- Sponsor
- Changhai Hospital
- Start
- Dec 2025
- Primary completion
- Dec 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in Non-muscle-invasive bladder cancer (NMIBC), sponsored by Changhai Hospital. Started Dec 2025; status: recruiting.
02
Drugs
toripalimab
03
Conditions
Non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT07307456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07307456.